Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

Findings presented at the Gastrointestinal Cancers Symposium showed the efficacy of Krazati and Erbitux for some patients with unresectable or metastatic colorectal cancer. Among heavily pretreated ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

although Amgen has also reported positive pivotal trial results in KRAS G12C-mutated colorectal cancer for Lumakras in combination with its own EGFR drug Vectibix (panitumumab). The CRC approval ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Learn more about whether Blueprint Medicines Corporation or Zai Lab Limited is a better investment based on AAII's A+ ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Cantor Fitzgerald adjusted its outlook on Amgen shares (NASDAQ:AMGN), reducing the price target from the previous $405.00 to $340.00. Despite the lowered price target, the firm maintained its ...

Nancy A. Grygiel, Senior Vice President and Chief Compliance Officer at Amgen Inc . (NASDAQ:AMGN), recently sold shares of the company's common stock. According to a filing with the Securities and ...

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.